M

    Monte Rosa Therapeutics Inc (GLUE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.94
    +0.56 (+4.19%)

    Market Cap: $1.14B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(11/22)
    Avg Surprise
    -68.01%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.56 - $0.10
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.38-9.5%
    60d ago$-0.38-9.5%
    30d ago$-0.38-9.5%
    7d ago$-0.35+0.0%
    Current$-0.35
    Revenue Consensus
    $19M
    Range$0 - $67M
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.48
    Range$-0.93 - $0.68
    7 analysts
    Revenue Consensus
    $10M
    Range$-29983430 - $148M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.48---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.43$-0.25-72.00%Miss-186.7%
    Mar 26
    		$-0.45$-0.38-18.42%Miss-178.9%
    Dec 25
    		$-0.55$-0.33-67.58%Miss-53.6%
    Sep 25
    		$-0.33$-0.35+5.71%Beat-13.8%
    Jun 25
    		$-0.15N/A+51.61%Beat+65.1%
    Mar 25
    		$0.57$-0.32+278.13%Beat+207.5%
    Dec 24
    		$-0.36$0.18-298.94%Miss+38.3%
    Sep 24
    		$-0.29$-0.47+38.30%Beat+58.6%
    Jun 24
    		$-0.43$-0.54+20.37%Beat+39.4%
    Mar 24
    		$-0.53$-0.58+8.62%Beat+18.5%
    Dec 23
    		$-0.58$-0.33-75.76%Miss+7.9%
    Sep 23
    		$-0.70$-0.74+5.41%Beat-20.7%
    Jun 23
    		$-0.71$-0.69-2.90%Miss-24.6%
    Mar 23
    		$-0.65$-0.68+4.41%Beat-27.5%
    Dec 22
    		$-0.63$-0.62-1.61%Miss+32.3%
    Sep 22
    		$-0.58$-0.59+1.69%Beat-34.9%
    Jun 22
    		$-0.57$-0.47-21.28%Miss+84.3%
    Mar 22
    		$-0.51$-0.54+5.56%Beat+83.3%
    Dec 21
    		$-0.93$-0.50-86.00%Miss+87.1%
    Sep 21
    		$-0.43$-0.44+2.27%Beat+85.8%
    Jun 21
    		$-3.63$-0.38-855.26%Miss-
    Mar 21
    		$-3.06$-0.59-418.64%Miss-
    Dec 20
    		$-7.18$0.00N/AMiss-
    Dec 19
    		$-3.04$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.92EV/EBITDA51.86x
    Price/FCF-44.10xFCF Yield-2.27%
    Profitability
    Profit Margin0.00%Operating Margin-548.00%
    ROE-42.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio10.58xQuick Ratio10.58x
    Trading Statistics
    Beta1.53Avg Volume1.19M
    52-Week High$25.7752-Week Low$4.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.42
    SMA 20$15.09
    SMA 50$19.51
    SMA 200$18.52
    EMA 10$14.46
    EMA 20$15.59
    EMA 50$17.66
    EMA 200$17.00

    MACD

    Line: -1.54Signal: -1.59Hist: 0.06

    ADX

    ADX: 38.9+DI: 12.0-DI: 33.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$16.95

    Bollinger Bands

    Upper Band$16.76
    Lower Band$13.41
    %B Position2221%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    34.3

    Momentum Oscillators

    Stoch %K21.2
    Stoch %D27.8
    Williams %R-73.9
    ROC (10d)-9.4%
    Momentum-1.44
    CCI (20d)-130.5
    MFI (14d)29.1

    Volatility Measures

    ATR (14d)$1.04(7.5%)
    StdDev (20d)0.84
    Hist Vol54.3%(High)

    Volume Flow

    VWAP$13.72
    OBV59.3M
    AD Line21.8M
    CMF (20d)-0.166

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.0x
    VWMA (20d)$15.09

    Pivot Points

    R3$14.93
    R2$14.61
    R1$14.00
    Pivot Point$13.68
    S1$13.07
    S2$12.75
    S3$12.14

    Advanced Oscillators

    TSI-35.99
    Ultimate Osc42.4
    KST-286.57

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M$8.75M$0
    Cost of Revenue$0$0$2.09M$0$0$0$2.06M$0$0$0$1.85M$0
    Gross Profit$8.97M$4.21M$2.78M$12.77M$23.19M$84.93M$60.65M$9.22M$4.70M$1.06M$-1,846,000$0
    Operating Expenses$58.10M$54.24M$52.50M$45.74M$38.75M$40.89M$47.64M$35.74M$37.34M$36.01M$34.86M$36.97M
    R&D$47.96M$44.07M$41.98M$36.68M$30.65M$32.19M$38.87M$27.62M$28.05M$27.03M$27.14M$28.31M
    SG&A$10.13M$10.18M$10.52M$9.06M$8.10M$8.70M$8.78M$8.13M$9.28M$8.98M$7.73M$8.66M
    Operating Income$-49,130,000$-50,034,000$-49,715,000$-32,975,000$-15,554,000$44.04M$13.00M$-26,527,000$-32,642,000$-34,947,000$-34,863,000$-36,968,000
    Interest Income$5.92M$5.59M$3.69M$2.75M$3.07M$3.44M$2.60M$2.89M$2.64M$2.44M$2.37M$2.23M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-43,189,000$-44,451,000$-46,076,000$-30,258,000$-11,096,000$47.71M$15.60M$-23,788,000$-30,058,000$-31,885,000$-33,274,000$-34,714,000
    Income Tax Expense$208,000$52,000$59,000$-3,177,000$1.20M$822,000$2.16M$71,000$252,000$83,000$-22,000$170,000
    Net Income$-43,397,000$-44,503,000$-46,135,000$-27,081,000$-12,295,000$46.88M$13.44M$-23,859,000$-30,310,000$-31,968,000$-33,252,000$-34,884,000
    EBITDA$-47,191,000$-48,013,000$-47,677,000$-30,909,000$-12,039,000$46.32M$15.07M$-24,577,000$-30,635,000$-32,430,000$-33,665,000$-35,107,000
    EBIT$-49,105,000$-50,042,000$-49,765,000$-33,004,000$-14,164,000$44.27M$13.01M$-26,680,000$-32,695,000$-34,327,000$-35,511,000$-36,941,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GLUE

    News

    Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive

    Monte Rosa Therapeutics (GLUE) recently initiated its MODeFIRe-1 Phase 2 trial for MRT-2359, which helped maintain investor interest despite recent stock price declines. While the company shows long-term gains, its current price-to-sales ratio of 43.2x suggests it is overvalued compared to peers and the broader biotech industry. Investors are cautioned to weigh the clinical progress against significant risks like potential trial setbacks and ongoing financial losses.

    Simply Wall Street•8/25/26•
    Neutral

    Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst Upgrade

    Monte Rosa Therapeutics (NASDAQ:GLUE) saw its shares rise 7.4% after TD Cowen upgraded the stock to a Strong Buy rating. Despite recent target price reductions from other firms and a missed earnings report, the company maintains a "Moderate Buy" consensus rating with an average target price of $28.50. Insider transactions show some selling activity, while institutional investors have adjusted their stakes in the company.

    MarketBeat•8/25/26•
    Somewhat-Bullish

    Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

    Guggenheim has reiterated its "Buy" rating for Monte Rosa Therapeutics (NASDAQ:GLUE), setting a $28 price target, which suggests a significant upside. Despite this positive outlook, the company recently reported an adjusted loss of $0.43 per share and revenue of $8.97 million, both falling short of analyst expectations. Institutional investors hold a substantial portion of the company's stock, while insiders have sold shares worth approximately $1.77 million in the last quarter.

    MarketBeat•8/25/26•
    Somewhat-Bullish

    Monte Rosa starts Phase 2 MRT-2359 prostate cancer trial

    Monte Rosa Therapeutics has initiated a Phase 2 trial (MODeFIRe-1) for its investigational molecular glue degrader MRT-2359 combined with apalutamide, targeting metastatic castration-resistant prostate cancer with AR mutations. The study aims to enroll up to 25 patients and will evaluate treatment responses and safety, building on previous data showing positive PSA responses in AR-mutant patients. Updated data from an earlier expansion arm is anticipated by year-end.

    grafa.com•8/24/26•
    Bullish

    Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

    Monte Rosa Therapeutics (NASDAQ:GLUE) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 12-month price target of $28.50, despite recent reductions in price targets by some analysts. The company's stock opened at $14.30, significantly below its 52-week high, after reporting quarterly revenues and EPS that missed analyst expectations. Insider sales of 81,778 shares worth $1.77 million were noted, while institutional investors, including a new position by BlackRock, hold nearly 80% of the company's shares.

    MarketBeat•8/24/26•
    Neutral

    Frequently Asked Questions About GLUE

    Does GLUE pay dividends?
    Monte Rosa Therapeutics Inc (GLUE) does not currently pay a regular dividend.
    What is GLUE's market cap?
    Monte Rosa Therapeutics Inc (GLUE) has a market capitalization of $1.14B with a current stock price of $13.94.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In